Global Liquid Biopsy Market to Reach $15.46 Billion by 2033

According to Renub Research Latest Report liquid biopsy market is expected to grow dramatically, reaching $15.46 billion by 2033, up from $4.29 billion in 2024, representing a robust CAGR of 15.3% over the forecast period. The market’s expansion is driven by the rising need for non-invasive cancer diagnostics, breakthroughs in biomarker technologies, and increasing adoption of personalized medicine, positioning liquid biopsy as a cornerstone of next-generation healthcare.

Understanding Liquid Biopsies

A liquid biopsy is a non-invasive diagnostic test that detects diseases such as cancer by analyzing biological fluids like blood. Unlike traditional tissue biopsies requiring surgical procedures, liquid biopsies use circulating biomarkers such as cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes.

These tests provide real-time insights into tumor dynamics, enabling early detection, monitoring of disease progression, and treatment response evaluation. Beyond oncology, liquid biopsies are increasingly applied in prenatal testing, organ transplant monitoring, and detection of genetic or chronic conditions, highlighting their critical role in personalized healthcare.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Sample Report

Key Drivers of Market Growth

Rising Global Cancer Incidence

Cancer prevalence is a primary driver for liquid biopsy adoption. These tests provide accurate, non-invasive alternatives for detecting cancers such as lung, breast, and colorectal cancer. In 2024, the United States alone is projected to record 2,001,140 new cancer cases and 611,720 deaths, emphasizing the need for efficient diagnostic tools.

Liquid biopsies are also being explored for monitoring chronic diseases such as cardiovascular and genetic disorders, further boosting market growth. Their non-invasive nature and ability to provide real-time data make them highly attractive for clinicians and patients alike.

Innovations in Biomarker and Molecular Technologies

Advancements in biomarker discovery and molecular diagnostics have significantly propelled liquid biopsy adoption. Techniques such as next-generation sequencing (NGS), ctDNA analysis, and exosome profiling improve sensitivity and specificity, enabling early detection and personalized treatment monitoring.

For example, in August 2024, Hitachi High-Tech Corporation partnered with Gencurix, Inc. to combine digital diagnostic technology with biomarker expertise, aiming to provide comprehensive cancer molecular diagnostics. Such innovations highlight the growing precision and integration of liquid biopsies in clinical workflows worldwide.

Shift Towards Non-Invasive Diagnostics

The global shift towards patient-centric, minimally invasive healthcare is fueling liquid biopsy adoption. These tests reduce risk, require minimal recovery time, and can be performed repeatedly, making them suitable for advanced-stage cancer patients. Increasing use in home-based or outpatient diagnostics further supports market growth, aligning with modern healthcare trends.

Regional Insights

United States

The U.S. dominates the global market, driven by high cancer prevalence, advanced healthcare infrastructure, and strong R&D investments. FDA approvals for liquid biopsy technologies have facilitated adoption across hospitals and diagnostic labs.

In February 2024, Myriad Genetics acquired assets from Intermountain Health, including the Precise Tumor Test, Precise Liquid Test, and IPG’s CLIA-certified laboratory, expanding its portfolio for early detection and monitoring of multiple cancer types.

Germany

Germany leads Europe in liquid biopsy adoption due to a strong healthcare system, biotech investments, and research focus. Regulatory frameworks support precision medicine, enabling rapid integration of new diagnostic technologies.

In September 2024, PreAnalytiX GmbH (a QIAGEN and BD joint venture) introduced the PAXgene Urine Liquid Biopsy Set, enabling reliable cfDNA analysis from urine using qPCR, digital PCR, and NGS, strengthening Germany’s position in advanced cancer diagnostics.

China

China is experiencing rapid market growth, driven by rising cancer rates and government initiatives promoting advanced diagnostics. Domestic and global biotech investments have accelerated research and innovation in early detection and precision medicine.

In August 2023, China’s National Medical Products Administration approved sunvozertinib for advanced NSCLC patients with EGFR exon 20 insertion mutations, emphasizing the country’s commitment to precision oncology.

Brazil

Brazil leads Latin America in liquid biopsy adoption, supported by increasing healthcare awareness and modernization of medical infrastructure. Early detection is critical in a country with high cancer prevalence, and government initiatives in healthcare and biotech investment have enhanced liquid biopsy penetration.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Market Segmentation

Product

Kits & Reagents

Platforms & Instruments

Services

Application

Cancer Therapeutics

Reproductive Health

Other Therapeutic Uses

Circulating Biomarkers

Circulating Tumor Cells (CTCs)

Circulating Tumor DNA (ctDNA)

Cell-Free DNA (cfDNA)

End-Users

Hospitals

Diagnostic Laboratories

Point-of-Care Testing Centers

Academic Institutes

Regional Coverage

Americas: U.S., Canada, Mexico, Brazil

Europe: UK, Germany, France, Italy, Spain, Netherlands

Asia-Pacific: China, Japan, India, South Korea, Australia

Middle East & Africa: UAE, South Africa

Key Market Players and Developments

F. Hoffmann-La Roche Ltd.

FDA approval for NSCLC companion diagnostics (Oct 2020)

Partnered with Lung Cancer Research Foundation and LCMC for early-stage lung cancer trials (June 2022)

Thermo Fisher Scientific Inc.

Launched digital PCR liquid biopsy assays (Nov 2022)

First assays measuring myeloid measurable residual disease (MRD) using DNA and RNA (Aug 2023)

Guardant Health

FDA approval of Guardant360 CDx for ESR1 mutant breast cancer (Jan 2023)

Launched Guardant360 Response, a blood-based test for immunotherapy monitoring (June 2021)

Illumina, Inc.

Launched TruSight Oncology 500 ctDNA v2 for genomic profiling (Nov 2023)

Collaborated with Bristol Myers Squibb for companion diagnostics (2021)

QIAGEN N.V.

Launched QIAseq targeted cfDNA ultra panels (Apr 2023)

Introduced Therascreen EGFR Plus RGQ PCR Kit (May 2023)

Exact Sciences Corporation

Acquired Prevention Genetics to expand hereditary cancer testing (Jan 2022)

Developed blood-based liquid biopsies for early detection and recurrence monitoring (Aug 2021)

Other major players include Bio-Rad Laboratories, Johnson & Johnson, Biocept Inc., Laboratory Corporation of America Holdings, all contributing to R&D, innovation, and market expansion.

Why Liquid Biopsies Are Transformational

Liquid biopsies offer significant advantages over traditional tissue biopsies, including:

Non-invasive procedures eliminating surgical risks

Real-time monitoring of treatment response and tumor evolution

Early detection before symptoms appear

Enhanced patient convenience with fewer hospital visits

Integration with personalized medicine, enabling tailored treatments

Such advantages position liquid biopsies as critical tools for modern oncology and healthcare innovation.

Future Outlook

The liquid biopsy market is poised for continued growth. Ongoing R&D investments, strategic partnerships, and regulatory approvals will accelerate adoption. Emerging markets like China and Brazil are expected to grow rapidly, while the U.S. and Germany continue to lead in innovation and regulatory support.

As global cancer rates rise and patients demand less invasive, more accurate diagnostic options, liquid biopsies are set to become standard in early detection, personalized therapy, and long-term patient monitoring. With a projected market value of $15.46 billion by 2033, liquid biopsies represent both a substantial business opportunity and a life-saving advancement in healthcare.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.